Key result
In isolated rat hearts, amiodarone and sotalol decreased contractility and cardiac output compared to placebo, whereas procainamide did not.
Why the study?
Direct comparison of antiarrhythmic agents on myocardial performance may guide drug selection in critically ill patients, but studies directly comparing multiple antiarrhythmics are lacking.
Do antiarrhythmic agents (procainamide, esmolol, amiodarone, sotalol) impair myocardial performance in an isolated rat heart model?
Do antiarrhythmic agents (procainamide, esmolol, amiodarone, sotalol) impair myocardial performance in an isolated rat heart model?
In an isolated rat heart model, amiodarone and sotalol depressed myocardial contractility and cardiac output, whereas procainamide did not negatively affect myocardial performance.
Answers are grounded in this paper and cite their sources.
May warrant caution with amiodarone or sotalol where contractility matters; leaves open translation to human myocardium.
Introduction: Direct comparison of the effects of antiarrhythmic agents on myocardial performance may be useful in choosing between medications in critically ill patients. Studies directly comparing multiple antiarrhythmic medications are lacking. The use of an experimental heart preparation permits examination of myocardial performance under constant loading conditions. Methods: Hearts of Sprague Dawley rats (n = 35, 402-507 g) were explanted and cannulated in working heart model with fixed preload and afterload. Each heart was then exposed to a 3-hour infusion of procainamide (20 µg/kg/min), esmolol (100 or 200 µg/kg/min), amiodarone (10 or 20 mg/kg/d), sotalol (80 mg/m 2 /d), or placebo infusions (n = 5 per dose). Cardiac output, contractility (dP/dT max ), diastolic performance (dP/dT min ), and heart rate were compared between groups over time by linear mixed modeling. Results: Compared with placebo, sotalol decreased contractility by an average of 24% ( P < .001) over the infusion period, as did amiodarone (low dose by 13%, P = .029; high dose by 14%, P = .013). Compared with placebo, mean cardiac output was significantly lower in animals treated with sotalol (by 22%, P = .016) and esmolol 200 μg/kg/min (by 23%, P = .012). Over time, amiodarone decreased cardiac output (20 mg/kg/d, β = −89 [−144, −33] μL/min 2 decrease, P = .002) and also worsened diastolic function, decreasing dP/dT min by ∼18% and 22% ( P = .032 and P = .011, low and high doses, respectively). Procainamide did not have a significant effect on any measures of systolic or diastolic performance. Conclusions: In isolated hearts, amiodarone and sotalol depressed myocardial contractility, cardiac output, and diastolic function. However, procainamide did not negatively affect myocardial performance and represents a favorable agent in settings of therapeutic equivalence.
No takes yet. Share an insight, caveat, or question.
Mackin et al. (2018) studied this question. Procainamide, esmolol, amiodarone, and sotalol vs. Placebo was evaluated on Cardiac output, contractility (dP/dT max), diastolic performance (dP/dT min), and heart rate. In isolated rat hearts, amiodarone and sotalol decreased contractility and cardiac output compared to placebo, whereas procainamide did not.
Synapse has enriched 10 related papers. Consider them for comparative context: